Evaluation of Prognostic Impact of Left Atrial Longitudinal Strain on Patients with Cardiac Amyloidosis

• Published in: Ankara Ueniversitesi Tip Fakültesi mecmuasi 2022-03, Vol.75 (1), p.42-47
• Main Authors: Tan, Türkan Seda, Korkmaz, Kübra, Tekin, Cemre Gül, Nazman, Hüseyin, Dinçer, İrem
• Format: Article
• Language: eng ; tur
• Subjects: Amyloidosis; Medical prognosis
• ISSN: 1307-5608; 0365-8104; 1307-5608
• DOI: 10.4274/atfm.galenos.2022.00921

Objectives: Immunoglobulin light chain cardiac amyloidosis (AL) is the most common systemic amyloidosis. Cardiac involvement associated with poor prognosis and biomarkers are used to determine the prognostic stages. Although echocardiographic parameters are used for the diagnosis of cardiac involvement, they are not established as the markers of disease severity. We sought to investigate whether left atrial longitudinal strain parameter predicts survival in patients with cardiac AL amyloidosis. Materials and Methods: Thirty-seven patients with cardiac amyloidosis were included into our study. Clinical and demographic data and transthoracic echocardiographic views were obtained from medical records. All patients were divided into two groups according to their survival. Results: The mean age of the study population was 63.9±10.8 years. Demographic characteristics and laboratory parameters except NT-proBNP were similar between two groups. NT-proBNP value was found as statistically higher in death caused group (p=0.02). In TTE parameters, the left atrial volume index was higher (p=0.02) however, peak atrial longitudinal strain (PALS) was reduced in death caused group (p=0.004). In Cox proportional regression method, PALS was found the most important predictor of survival after adjustment for NT-proBNP [hazard ratio (95% confidence interval): 0.92 (0.84-0.98); p=0.01]. Conclusion: In our study we determined that PALS was highly associated with survival in patients with cardiac AL amyloidosis. We thought that larger, prospective studies are necessary to evaluate the prognostic impact of PALS in patients with cardiac AL amyloidosis.